Development of a CRISPR-Cas13-based antiviral strategy against hepatitis E virus

Background & Aims: Effective antiviral drugs remain unavailable for many clinically relevant pathogens, including the hepatitis E virus (HEV). This study aimed to evaluate the CRISPR/Cas13d system as a potential antiviral strategy against HEV. Methods: We developed a reporter assay to screen CRI...

Descripció completa

Dades bibliogràfiques

Autors principals:	Emely Richter, Mara Klöhn, Maximilian K. Nocke, Marcel Edgar Friedrich, Daniel Todt, Eike Steinmann, Yannick Brüggemann
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2026-07-01
Col·lecció:	JHEP Reports
Matèries:	Hepatitis E virus (HEV) CRISPR-Cas13 Antivirals
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2589555926001564
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!